Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$960.50K$960.50Kderived+195.7% vs Q4 2022 Net Income-$2.21M-$2.21MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$546,935+393.7% Operating Incomederived-$1,768,010N/M Operating Cash Flowderived$1,573N/M Margins · derivedGross margin56.9%+22.8 pt vs Q4 2022
Operating margin-184.1%+239.4 pt vs Q4 2022
Net margin-230.0%+294.9 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end